Literature DB >> 9786174

Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo.

B P Kennedy1, S K Mahata, D T O'Connor, M G Ziegler.   

Abstract

Catestatin (bovine chromogranin A(344-364); RSMRLSFRARGYGFRGPGLQL), reduces catecholamine secretion from chromaffin cells in vitro. We investigated the effects of this peptide on catecholamine release and blood pressure in vivo. Intravenous catestatin reduced pressor responses to activation of sympathetic outflow by electrical stimulation in rats, and the catestatin effect persisted even after adrenergic (alpha plus beta) blockade. Catestatin did not alter plasma norepinephrine levels, but increased plasma epinephrine 11-fold. Catestatin also blunted pressor responses to exogenous neuropeptide Y agonists. A control peptide (chromogranin A(141-160)) did not alter pressor or catecholamine responses to electrical stimulation. Pretreatment with a histamine H1 receptor antagonist blocked both the vasodepressor response to catestatin and the elevation in plasma epinephrine. Catestatin elevated endogenous circulating histamine 21-fold, and exogenous histamine mimicked both the epinephrine elevation and the vasodepressor actions of catestatin. We conclude that catestatin is a potent vasodilator in vivo whose actions appear to be mediated, at least in part, by histamine release and action at H1 receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786174     DOI: 10.1016/s0196-9781(98)00086-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  44 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

Review 2.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 3.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

4.  Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway.

Authors:  Malapaka Kiranmayi; Venkat R Chirasani; Prasanna K R Allu; Lakshmi Subramanian; Elizabeth E Martelli; Bhavani S Sahu; Durairajpandian Vishnuprabu; Rathnakumar Kumaragurubaran; Saurabh Sharma; Dhanasekaran Bodhini; Madhulika Dixit; Arasambattu K Munirajan; Madhu Khullar; Venkatesan Radha; Viswanathan Mohan; Ajit S Mullasari; Sathyamangla V Naga Prasad; Sanjib Senapati; Nitish R Mahapatra
Journal:  Hypertension       Date:  2016-06-20       Impact factor: 10.190

Review 5.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

6.  Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

Authors:  Sucheta M Vaingankar; Ying Li; Angelo Corti; Nilima Biswas; Jiaur Gayen; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-15       Impact factor: 3.107

Review 7.  Secretogranin III: a diabetic retinopathy-selective angiogenic factor.

Authors:  Wei Li; Keith A Webster; Michelle E LeBlanc; Hong Tian
Journal:  Cell Mol Life Sci       Date:  2017-08-30       Impact factor: 9.261

Review 8.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

9.  Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.

Authors:  Maria-Giulia Perrelli; Francesca Tullio; Carmelina Angotti; Maria Carmela Cerra; Tommaso Angelone; Bruno Tota; Giuseppe Alloatti; Claudia Penna; Pasquale Pagliaro
Journal:  Pflugers Arch       Date:  2013-01-15       Impact factor: 3.657

10.  Chromogranin A polymorphisms are associated with hypertensive renal disease.

Authors:  Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.